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To investigate whether immunization with Escherichia coli JS boiled cells induces antibodies
directed at deep core structures, antibodies against JS lipopolysaccharide (LPS), Re LPS t and
Iipid A were measured in the serum of 70 volunteers before and 2 weeks after immunization.
To improve the sensitivity and the specificity ofELISAt complexes of core LPS with high-density
lipoproteins were used instead of free core LPS as antigens. A median three-fold increase in anti-
bodies directed against J5 LPS was observed, but no significant increase in the antibodies against
Re LPS or lipid A was found. Since JS antiserum did not react with several smooth LPS or with
Re LPS and lipid At cross-reactivity could not be demonstrated. Thus, immunization of volun-
teers with E. coliJS produced a modest specific antibody response against J5 LPS. The mecha-
nism of protection previously observed with J5 antiserum remains unclear.
Two clinical trials have suggested that human serum from
volunteers immunized with the rough mutant Escherichia coli
J5 (J5 antiserum) is effective as an adjunct in the treatment
[1] or prevention [2] of gram-negative shock. However, the
mechanism of protection against gram-negative septic shock
afforded by J5 antiserum remains unknown. Rough mutants
of gram-negative bacilli expose on their surface various parts
of the core region of the lipopolysaccharide (LPS) that are
hidden on smooth bacteria by the O-side chains and are there-
fore poorly accessible to' immunologic reactions. Since the
core LPS is relatively conserved phylogenetically, a working
hypothesis is that anti-core LPS 'antibodies may cross-react
with various gram-negative bacteria and possibly be protec-
tive against a wide range of gram-negative bacteria. However,
the outcome of patients correlated weakly [1] or not at all (un-
published data) with the levels 01J5 LPS antibodies measured
in the sera administered.
J5 LPS is a complex molecule composed of core saccha-
rides (heptose, glucose, N-acetylglucosamine, and 3-deoxy-
o-manno-2-octulosonate [KDOD, of phosphate, ethanolamine,
and of the toxic lipid A [3]. Immunization with J5 vaccine
might therefore induce a mixture of antibodies against vari-
ous epitopes of J5 LPS. A hypothesis raised to explain the
lack of correlation between protection and levels of J5 LPS
antibodies was that only antibodies directed to the immuno-
dominant core sugars are detected when measuring J5 LPS
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antibodies with an ELISA or with an indirect hemagglutina-
tion test. If the postulated cross-protective antibodies are
directed at deeper core structures, such as lipid A or the lipid
A-KDO region, they may remain undetected when the whole
J5 LPS molecule is used as antigen in serologic tests, because
these deeper structures may be hidden by the outermost core
sugars. •
To investigate this hypothesis, we measured by ELISA the
antibody response to lipid A and Re LPS (composed of lipid
A and KDO) after 70 healthy volunteers were vaccinated with
Escherichia coli J5. Core LPS, especially Re LPS and lipid
A, are hydrophobic structures with limited solubility and self-
aggregating properties. They are difficult to use as antigens
in ELISA because the coating of the plates may be poor and
because nonspecific sticking of immunoglobulins to hydro-
phobic structures may be observed [4]. We have noted that
complexing LPS to high-density lipoproteins (HDL) , a natu-
ral carrier of LPS t modified the physicochemical state of core
LPS and that use ofHDL-LPS complexes to coat ELISA plates
increased both the sensitivity and the specificity of the test
compared with coating with free-core LPS [4].
In the present study, we used complexes of LPS with HDL
instead of free LPS as coating antigens [4]. To study whether
J5 vaccine produces a polyclonal antibody increase, we also
measured the levels of antibody directed against LPS from
E. coli 0111 (0111 LPS) and against a mixture of LPS from
seven different, smooth gram-negative strains and total IgG
and IgM levels.
Materials and Methods
Immunization of volunteers. The procedure was performed as
previously described [1]. E. coli J5 vaccine (provided by E. J. Zie-
gler, San Diego) was prepared from stationary-phase E. coliJ5bac-
terial cells grown in trypticase soybroth, harvested bycentrifugation,
washed three times in sterile 0.15 M sodium chloride, boiled for
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2.5 h, adjusted to 5 x 109 bacteria/ml, and conserved with 5 gIl
of phenol. Healthy volunteers were immunized subcutaneously with
two l-ml injections of E. coli J5 vaccine simultaneously in two sepa-
rate sites and with two more I-ml injections 48 h later. Plasma sam-
ples were collected before and 2 weeks after the first injections. The
plasma were used during a study of prevention of gram-negative septic
shock in high-risk surgical patients [2], and aliquots were kept at
-70°C for antibody determinations.
LPS. LPS from E. coli 0111:B4 (0111 LPS,) E. coli 026, E.
coli 0127, Salmonella. minnesota S128, Salmonella enteritidis,
Salmonella typhimurium, and Serratia marcescens were obtained
from Sigma Chemical (St. Louis). LPS from E. coli J5 mutant (J5
LPS), LPS from S. minnesota R595 mutant (R595 LPS), and lipid
A from S. minnesota R595 mutant (R595 lipid A) were obtained
from Ribi Immunochem Research (Hamilton, MT). LPS from E.
coli D3lm4 (D3lm4 LPS) (an Re-type rough mutant) and the lipid
A extracted from it (D3lm4 lipid A) were obtained from List Bio-
logical Laboratories (Campbell, CA). Lyophilized LPS were recon-
stituted in pyrogen-free water to a concentration of 1 mglml.
Triethylamine (0.5% vol/vol) was added for Re LPS and lipid A.
, Determination ofantibody levels by EliSA. Complexes of LPS
with HDL were used instead of free LPS as coating antigens (see
[4]). Controls with HDL alone were included and background values
from these wells were subtracted from the readings. Hyperimmune
rabbit antisera specific for E. coli 0111, J5, D3lm4 LPS, S. min-
nesota R595 LPS, and for lipid A extracted both from S. minnesota
R595 and from E. coli D3lm4 were used to demonstrate the ade-
quate presence of antigens on the plates. The assay was standardized
with immunopurified human a~ti-J5 LPS IgG or IgM antibodies pre-
pared as described [4]. A standard curve was established with the
immunopurified antibodies for the determination of the levels of an-
tibodies in the test samples. For the purpose of this study, the same
standard curve was used to estimate the concentrations of all anti-
LPS antibodies measured simultaneously with J5 LPS antibodies.
The sensitivity of the assay was 0.5 ~glml for IgG or IgM antibod-
ies. For antibodies to E. coli D3lm4 LPS and lipid A, which were
assayed later, the results were reported as arbitrary units (AU; opti-
cal densities x dilutions).
IgG and IgM serum levels. Total IgG and IgM serum levels were
measured by standard methods using a Behring nephelometer ana-
lyzer (Hoechst-Behring).
Statistical methods. Antibody levels before and after immuni-
zation were compared by the nonparametric Wilcoxonpaired-sample
test.
Results
Antibodies to J5 LPS. Of the 70 volunteers before immu-
nization, 60 %and 96%had detectable levels of IgG and IgM
antibodies, respectively, against J5 LPS. These values increased
to 86 % and 99 % after vaccination with E. coli J5. The me-
dian increase in the levels of antibodies directed to J5 LPS
was 3-fold for IgG and a 3.25-fold for IgM (table 1).This slight
increase contrasted with the several hundredfold increase ob-
served in rabbits immunized intravenously: titers usually
increased from 1:100-1:200 before immunization to 1:25,600-
1:102,400 after immunization with boiled bacterial cells.
Table 1. Antibody levels in 70 volunteers immunized with
Escherichia coli J5.
Median levels of anti-LPS antibody (ug/rnl)
Before After
Antibody, immunization immunization Fold
antigen* (range) <range) increase P
IgG
J5 LPS 4 «0.5-87) 13 «0.5-251) 3.25 <10-6
R595 LPS 5 «0.5-116) 5 «0.5-135) 1 NS
R595 lipid A 3 «0.5-41) 3 «0.5-69) 1 NS
0111 LPS <0.5 «0.5-30) <0.5 «0.5-50) 1 NS
Smooth LPSt 21 «0.5-140) 26 «0.5-117) 1.24 NS
IgM
J5 LPS 3 «0.5-33) 9 «0.5-53) 3 <10-6
R595 LPS 1 «0.5-8) 1 «0.5-5) 1 NS
R595 lipid A <0.5 «0.5-3) <0.5 «0.5-2) 1 NS
0111 LPS 1 «0.5-14) 1 «0.5-14) 1 NS
Smooth LPSt 4 «0.5-26) 4 «0.5-27) 1 NS
NOTE. LPS, lipopolysaccharide.
* Complexes of high-density lipoproteins with LPS or lipid A were used to coat
plates.
t Mixture of LPS from seven smooth bacterial strains (see text).
Antibodies to Re LPS and to lipid A. Ofvolunteers before
immunization, 67 % and 69 %, respectively, had detectable
IgG and IgM antibodies against S. minnesota ReLPS and 59%
and 16% against S. minnesota lipid A. Overall, these values
did not increase significantly after vaccination, and there was
no significant increase of the antibody levels in the subgroup
of volunteers with detectable preimmune levels (table 1).
Since antigenic and structural differences exist between the
core regions of S. minnesota and E. coli, we measured anti-
bodies against the LPS of a Re mutant of E. coli (strain D3lm4)
and against its lipid A in the sera of 21 volunteers randomly
selected from our series. Before immunization with E. coli
J5, the median (range) levels were 6 AU (0-64) for IgG and
2 (0-21) for IgM anti-D3lm4 LPS antibodies, and 2 (0-31)
and 9 (0-55) AU, respectively, for anti-D3lm4 lipid A anti-
bodies. There was no statistically significant increase in any
of these antibodies after immunization. In only four volun-
teers was some increase (less than threefold) in the levels of
one or several antibodies observed.
Antibodies to LPS from smooth bacteria and total immu-
noglobulin levels. No significant increase in specific IgG or
IgM antibodies against LPS from E. coli 0111 (the parent
of the J5 mutant) was observed. A slight increase of the me-
dian IgG antibody level against the mixture of LPS from seven
smooth bacterial strains (1.24-fold) was not statistically
significant and of doubtful biological importance. IgM anti-
bodies directed against the same seven antigens did not in-
crease (table 1).
The total serum IgG or IgM levels were measured in 10
volunteers randomly selected from our group: The mean (SD)
IgG serum levels before and after immunization were 9.4 (1.4)
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gil and 9.2 (1.1) gil, and the mean (SD) IgM serum levels were
1.0 (.04) gil and 1.0 (.05) gil, respectively.
Discussion
The current knowledge of the protective activity of anti-
body to endotoxin core was recently reviewed [5]. There is
no direct and convincing proof so far that the protection ob-
served with polyclonal antisera to rough mutants in animal
experiments [6-8] is due to cross-reactive anti-LPS antibod-
ies (see [9]). The protection reported with some monoclonal
antibodies [10-12] needs confirmation [13-15]. In humans,
there has been a discrepancy in clinical trials between the pro-
tection afforded byJ5 antiserum and the weak or lack of corre-
lation with the levels of J5 LPS antibodies measured in sera
administered to patients.
In the present study, we found that immunization of volun-
teers with E. coli J5 did not result in a marked elevation of
anti-J5 LPS antibodies, or in an elevation of anti-lipid A, anti-
Re LPS, or anti-smooth LPS antibodies. This further raises
the question of the mechanism of protection afforded by anti-
J5 serum or plasma. One possible explanation for this dis-
crepancy is that the antibody responsible for protection has
not been accurately measured by the serologic methods used.
Detection of antibodies to the various core LPS is difficult
because of the limited solubility and self-aggregating proper-
ties of hydrophobic core LPS, which may lead to nonspecific
binding of antibodies and to irregular coating of ELISA plates.
To avoid these problems, we modified the physicochemical
state of core LPS by complexing it to HDL, a natural carrier
of HDL in vivo, and used HDL-LPS complexes to coat the
plates. This method has been shown to increase the sensitiv-
ity and the specificity of the detection of core LPS or lipid
A antibodies [4]. In addition, the core region itself shows
significant inter- and intraspecies differences in its composi-
tion [13], and type-specific antibodies are elicited after im-
munization with rough mutants. The structures most likely
to induce broadly cross-reactive anti-LPS antibodies are the
most conserved parts, that is, lipid A or the lipid A-KDO
region. Therefore, if lipid A or lipid A-KDO antibodies are
a subset of J5 LPS antibodies, their detection might be ob-
scured by the quantitatively predominant type-specific J5 LPS
antibodies. Moreover, since LPS in outer membranes is het-
erogeneous [16], the innermost region of LPS may be exposed
at the surface of the whole J5 bacteria, whereas only com-
plete LPS with core sugars may be present in the J5 LPS ex-
tracted by chemical methods. Thus, immunization with whole
J5 bacteria would induce core LPS antibodies not detectable
when using purified J5 LPS as antigen.
We investigated whether J5 vaccine induced the produc-
tion of antibodies against lipid A or the lipid A-KDO region
that would not be adequately detected by ELISA using J5 LPS
as antigen. We could not detect significant increases of anti-
bodies to two lipid A and two Re LPS extracted both from
S. minnesota R595 or from E. coli D3lm4. Since the use of
HDL-LPS complexes instead of free LPS as antigen may mask
epitopes of the core LPS, it remains possible that antibodies
against these hidden epitopes may be missed. This seems un-
likely, however, because monoclonal antibodies directed
against well-defined epitopes of core LPS easily recognize
their epitopes within HDL complexes [4]. Our results ques-
tion the role of antibodies to lipid A or to lipid A-KDO as
protective factors in J5 antiserum, although these negative
findings must be compared with those of clinical studies (now
underway) with anti-lipid A monoclonal antibodies and with
purified intravenous immunoglobulins enriched in anti-Re LPS
antibodies.
Another possible explanation for the discrepancy between
the protection afforded by J5 antiserum and the weak anti-J5
LPS antibody increase observed is that the factor responsible
for the protection is a nonspecific polyclonal antibody increase
rather than cross-protective anti-core LPS antibodies. Indeed,
studies in rabbits suggest that a polyclonal response against
o antigens may occur after intravenous immunization with
J5 bacteria [17]. However, the present data suggest that this
is unlikely in man, because there was neither a significant
increase in antibodies to LPS from smooth gram-negative bac-
teria nor an increase in the total IgG or IgM serum levels.
Alternative explanations may be that J5 vaccine increased
nonspecifically some unrecognized acute-phase reactants
capable of neutralizing LPS, altering its metabolism, or coun-
teracting the biologic effects of humoral or cellular factors
released by the stimulation of LPS. Additional studies are
needed to explore these possibilities.
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